Chembio Diagnostics 주식 주식분석 | 주식가격 | 뉴스 | CEMI | US1635722093 | A1JY4D

날짜	Chembio Diagnostics 주식 가격
	0.46 undefined
	0.45 undefined

날짜	Chembio Diagnostics 매출	Chembio Diagnostics EBIT	Chembio Diagnostics 이익
2025e	35.78 백만 undefined	-19.9 백만 undefined	-34.8 백만 undefined
2024e	36.92 백만 undefined	-26.38 백만 undefined	-40.29 백만 undefined
2023e	38.86 백만 undefined	-35.67 백만 undefined	-47.57 백만 undefined
2022	49.52 백만 undefined	-20.4 백만 undefined	-23.29 백만 undefined
2021	47.82 백만 undefined	-24.01 백만 undefined	-33.9 백만 undefined
2020	32.47 백만 undefined	-21.95 백만 undefined	-25.52 백만 undefined
2019	34.46 백만 undefined	-12.61 백만 undefined	-13.68 백만 undefined
2018	34.58 백만 undefined	-7.64 백만 undefined	-7.87 백만 undefined
2017	24.02 백만 undefined	-6.45 백만 undefined	-6.37 백만 undefined
2016	17.87 백만 undefined	-7.57 백만 undefined	-13.35 백만 undefined
2015	24.26 백만 undefined	-3.55 백만 undefined	-2.4 백만 undefined
2014	27.65 백만 undefined	-1.55 백만 undefined	-1.14 백만 undefined
2013	29.55 백만 undefined	1 백만 undefined	530,000 undefined
2012	25.61 백만 undefined	1.45 백만 undefined	940,000 undefined
2011	19.39 백만 undefined	1.09 백만 undefined	6.21 백만 undefined
2010	16.7 백만 undefined	2.57 백만 undefined	2.51 백만 undefined
2009	13.83 백만 undefined	320,000 undefined	310,000 undefined
2008	11.05 백만 undefined	-2.07 백만 undefined	-1.95 백만 undefined
2007	9.23 백만 undefined	-2.88 백만 undefined	-8.27 백만 undefined
2006	6.5 백만 undefined	-4.58 백만 undefined	-8.21 백만 undefined
2005	3.94 백만 undefined	-3.3 백만 undefined	-6.77 백만 undefined
2004	3.31 백만 undefined	-3.11 백만 undefined	-5.04 백만 undefined
2003	0 undefined	-10,000 undefined	0 undefined

	매출	EBIT	이익
2003	0 USD	-10,000 USD	0 USD
2004	3.31 백만 USD	-3.11 백만 USD	-5.04 백만 USD
2005	3.94 백만 USD	-3.3 백만 USD	-6.77 백만 USD
2006	6.5 백만 USD	-4.58 백만 USD	-8.21 백만 USD
2007	9.23 백만 USD	-2.88 백만 USD	-8.27 백만 USD
2008	11.05 백만 USD	-2.07 백만 USD	-1.95 백만 USD
2009	13.83 백만 USD	320,000 USD	310,000 USD
2010	16.7 백만 USD	2.57 백만 USD	2.51 백만 USD
2011	19.39 백만 USD	1.09 백만 USD	6.21 백만 USD
2012	25.61 백만 USD	1.45 백만 USD	940,000 USD
2013	29.55 백만 USD	1 백만 USD	530,000 USD
2014	27.65 백만 USD	-1.55 백만 USD	-1.14 백만 USD
2015	24.26 백만 USD	-3.55 백만 USD	-2.4 백만 USD
2016	17.87 백만 USD	-7.57 백만 USD	-13.35 백만 USD
2017	24.02 백만 USD	-6.45 백만 USD	-6.37 백만 USD
2018	34.58 백만 USD	-7.64 백만 USD	-7.87 백만 USD
2019	34.46 백만 USD	-12.61 백만 USD	-13.68 백만 USD
2020	32.47 백만 USD	-21.95 백만 USD	-25.52 백만 USD
2021	47.82 백만 USD	-24.01 백만 USD	-33.9 백만 USD
2022	49.52 백만 USD	-20.4 백만 USD	-23.29 백만 USD
2023e	38.86 백만 USD	-35.67 백만 USD	-47.57 백만 USD
2024e	36.92 백만 USD	-26.38 백만 USD	-40.29 백만 USD
2025e	35.78 백만 USD	-19.9 백만 USD	-34.8 백만 USD

2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022

0	0.04	0.23	4.29	2.83	1.21	1.07	2.14	3.01	2.95	9.65	4.61	5.38	10.55	3.79	12.52	18.27	23.07	28.77	18.18
0	0.17	1.26	1.35	0.95	0.81	1.78	3.95	3	4.82	4.59	8.34	2.42	3.38	2.09	7.37	3.66	3.38	11.44	6.54
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	12.19
0	0.54	0.69	1.11	1.45	1.82	1.56	1.35	2.3	2.49	3.19	3.64	3.58	3.34	4.42	7.85	9.6	12.52	12.92	7.72
0	0.47	0.29	0.2	0.24	0.23	0.27	0.2	0.68	0.75	1.1	1.07	1.26	0.84	0.55	0.7	0.69	0.78	2.1	3.83
0	1.22	2.47	6.95	5.47	4.07	4.68	7.64	8.99	11.01	18.53	17.66	12.64	18.11	10.85	28.44	32.22	39.75	55.23	48.45
0	0.19	0.44	0.6	0.83	0.88	0.57	0.81	1.06	1.43	1.98	2.8	2.37	1.71	1.91	2.87	13.17	15.03	14.64	13.72
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0.26	0.94	0.7	0.6	0.5	0.4	0.33	0.26	0.1	0	1.6	3.88	3.91	3.65	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.67	4.98	5.87	5.96	3.02	0
0	0.03	0.11	0.35	0.03	0.03	0.38	0.04	4.93	4.5	3.65	4.3	5.71	0.75	0.59	0.72	0.54	0.51	0.36	0.43
0	0.22	0.55	0.95	1.12	1.85	1.65	1.45	6.49	6.33	5.96	7.36	8.18	2.46	5.77	12.45	23.49	25.15	18.02	14.16
0	1.44	3.02	7.9	6.59	5.92	6.33	9.09	15.48	17.34	24.49	25.02	20.82	20.57	16.62	40.89	55.71	64.9	73.25	62.61

0.18	2.5	5.89	12.72	0.61	0.62	0.62	0.62	0.08	0.08	0.09	0.1	0.1	0.12	0.12	0.17	0.18	0.2	0.3	0.37
0.19	9.08	14.03	19.96	39	39.25	39.45	39.66	40.68	41.12	46.88	47.56	47.89	60.72	62.82	90.95	95.43	124.96	165.77	172.28
-0.37	-12.1	-18.87	-27.07	-35.35	-37.29	-36.99	-34.47	-28.26	-27.32	-26.79	-27.93	-30.33	-43.67	-50.04	-57.91	-71.59	-97.11	-131.01	-154.3
0	0	0	0	0	0	0	0	0	0	0	0	0	0	180	110	10	-90	-592.37	-337.29
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	-0.52	1.05	5.61	4.26	2.58	3.08	5.81	12.5	13.88	20.18	19.73	17.66	17.17	13.08	33.32	24.03	27.96	34.47	18
0	1.1	1.48	1.71	2.18	2.38	0.66	0.88	1.26	1.69	1.82	1.98	1.26	1.44	1.49	3.62	3.14	5.73	7.75	3.34
0	0.18	0.12	0.09	0	0	1.24	1.17	1.53	1.62	2.49	2.97	1.54	1.58	1.55	2.27	2.95	4.96	6.27	17.3
0	0.28	0.18	0	0.04	0	1.24	0.94	0	0.02	0	0.34	0.35	0.39	0.05	0.42	0.13	1.61	0	0
0	50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0.05	0.04	0.04	0.02	0.02	0.03	0.08	0.07	0.05	0	0	0	0	0	0.21	0.22	0.06	1.27	18.65
0	1.66	1.82	1.84	2.24	2.4	3.17	3.07	2.86	3.38	4.31	5.29	3.15	3.41	3.09	6.52	6.44	12.36	15.28	39.3
0	0.07	0.04	0.01	0.08	0.06	0.05	0.2	0.13	0.08	0	0	0	0	0.1	0.17	17.82	18.37	17.73	0.09
0	0	0	0	0	0	0	0	0	0	0	0	0	0	340	890	470	70	0	0
0	0.21	0.1	0.45	0	0.88	0	0	0	0	0	0	0	0	0	0	6.97	6.33	5.98	5.43
0	0.28	0.14	0.46	0.08	0.94	0.05	0.2	0.13	0.08	0	0	0	0	0.44	1.06	25.26	24.77	23.7	5.51
0	1.94	1.96	2.3	2.32	3.34	3.22	3.27	2.99	3.46	4.31	5.29	3.15	3.41	3.53	7.58	31.7	37.13	38.99	44.81
0	1.42	3.01	7.91	6.58	5.92	6.3	9.08	15.49	17.34	24.49	25.02	20.81	20.58	16.61	40.9	55.73	65.09	73.46	62.82

2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
0	-3	-3	-5	-2	-1	0	2	6	0	0	-1	-2	-13	-6	-7	-13	-25	-33	-23
0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	1	2	2	2
0	0	0	0	0	0	0	0	-5	0	0	0	-1	5	0	0	0	0	0	0
0	0	0	0	0	0	0	-1	0	-1	0	-3	3	0	0	-5	1	2	-8	2
0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	1	8	5
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	-2	-4	-4	-1	-1	0	1	2	0	2	-3	1	-6	-5	-11	-9	-18	-30	-12
0	0	0	0	0	0	0	0	0	0	0	-1	-1	0	-1	-1	-3	-4	-1	-1
0	0	0	0	0	0	0	0	0	0	0	-1	-1	0	-1	-6	-3	-4	-1	-1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-5	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	18	0	0	0
0	1	4	8	0	0	0	0	0	0	5	0	0	12	0	27	0	28	38	4
0	2	4	8	0	0	0	0	0	0	5	0	0	12	0	27	18	27	38	3
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	4	-1	-1	0	1	0	0	6	-5	0	5	-6	8	5	4	5	-10
0	-2.71	-4.35	-4.58	-1.76	-1.59	-0.14	0.84	1.54	-0.11	1.39	-5.27	0.76	-6.82	-6.06	-13.25	-12.86	-23.06	-32.74	-14.15
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Chembio Diagnostics 브루토마진	Chembio Diagnostics 이익 마진	Chembio Diagnostics EBIT-마진	Chembio Diagnostics 이익 마진
2025e	22.1 %	-55.62 %	-97.26 %
2024e	22.1 %	-71.46 %	-109.12 %
2023e	22.1 %	-91.8 %	-122.44 %
2022	22.1 %	-41.2 %	-47.03 %
2021	27.86 %	-50.2 %	-70.9 %
2020	26.49 %	-67.6 %	-78.6 %
2019	35.03 %	-36.59 %	-39.7 %
2018	34.64 %	-22.09 %	-22.76 %
2017	46.17 %	-26.85 %	-26.52 %
2016	47.29 %	-42.36 %	-74.71 %
2015	43.24 %	-14.63 %	-9.89 %
2014	39.1 %	-5.61 %	-4.12 %
2013	41.62 %	3.38 %	1.79 %
2012	42.13 %	5.66 %	3.67 %
2011	48.43 %	5.62 %	32.03 %
2010	48.5 %	15.39 %	15.03 %
2009	42.37 %	2.31 %	2.24 %
2008	34.84 %	-18.73 %	-17.65 %
2007	30.34 %	-31.2 %	-89.6 %
2006	24.77 %	-70.46 %	-126.31 %
2005	33.76 %	-83.76 %	-171.83 %
2004	21.15 %	-93.96 %	-152.27 %
2003	22.1 %	0 %	0 %

	브루토마진	EBIT-마진	이익 마진
2003	22.1 %	0 %	0 %
2004	21.15 %	-93.96 %	-152.27 %
2005	33.76 %	-83.76 %	-171.83 %
2006	24.77 %	-70.46 %	-126.31 %
2007	30.34 %	-31.2 %	-89.6 %
2008	34.84 %	-18.73 %	-17.65 %
2009	42.37 %	2.31 %	2.24 %
2010	48.5 %	15.39 %	15.03 %
2011	48.43 %	5.62 %	32.03 %
2012	42.13 %	5.66 %	3.67 %
2013	41.62 %	3.38 %	1.79 %
2014	39.1 %	-5.61 %	-4.12 %
2015	43.24 %	-14.63 %	-9.89 %
2016	47.29 %	-42.36 %	-74.71 %
2017	46.17 %	-26.85 %	-26.52 %
2018	34.64 %	-22.09 %	-22.76 %
2019	35.03 %	-36.59 %	-39.7 %
2020	26.49 %	-67.6 %	-78.6 %
2021	27.86 %	-50.2 %	-70.9 %
2022	22.1 %	-41.2 %	-47.03 %
2023e	22.1 %	-91.8 %	-122.44 %
2024e	22.1 %	-71.46 %	-109.12 %
2025e	22.1 %	-55.62 %	-97.26 %

날짜	Chembio Diagnostics 주당 매출	Chembio Diagnostics EBIT 당 주식	Chembio Diagnostics 주당 이익
2025e	0.97 undefined	0 undefined	-0.95 undefined
2024e	1.01 undefined	0 undefined	-1.1 undefined
2023e	1.06 undefined	0 undefined	-1.3 undefined
2022	1.53 undefined	-0.63 undefined	-0.72 undefined
2021	1.97 undefined	-0.99 undefined	-1.4 undefined
2020	1.7 undefined	-1.15 undefined	-1.34 undefined
2019	2.03 undefined	-0.74 undefined	-0.81 undefined
2018	2.4 undefined	-0.53 undefined	-0.55 undefined
2017	1.95 undefined	-0.52 undefined	-0.52 undefined
2016	1.68 undefined	-0.71 undefined	-1.26 undefined
2015	2.52 undefined	-0.37 undefined	-0.25 undefined
2014	2.9 undefined	-0.16 undefined	-0.12 undefined
2013	3.1 undefined	0.11 undefined	0.06 undefined
2012	2.97 undefined	0.17 undefined	0.11 undefined
2011	2.27 undefined	0.13 undefined	0.73 undefined
2010	1.88 undefined	0.29 undefined	0.28 undefined
2009	1.47 undefined	0.03 undefined	0.03 undefined
2008	1.44 undefined	-0.27 undefined	-0.25 undefined
2007	5.04 undefined	-1.57 undefined	-4.52 undefined
2006	5.04 undefined	-3.55 undefined	-6.36 undefined
2005	4.1 undefined	-3.44 undefined	-7.05 undefined
2004	4.41 undefined	-4.15 undefined	-6.72 undefined
2003	0 undefined	-0 undefined	0 undefined

	주당 매출	EBIT 당 주식	주당 이익
2003	0 USD	-0 USD	0 USD
2004	4.41 USD	-4.15 USD	-6.72 USD
2005	4.1 USD	-3.44 USD	-7.05 USD
2006	5.04 USD	-3.55 USD	-6.36 USD
2007	5.04 USD	-1.57 USD	-4.52 USD
2008	1.44 USD	-0.27 USD	-0.25 USD
2009	1.47 USD	0.03 USD	0.03 USD
2010	1.88 USD	0.29 USD	0.28 USD
2011	2.27 USD	0.13 USD	0.73 USD
2012	2.97 USD	0.17 USD	0.11 USD
2013	3.1 USD	0.11 USD	0.06 USD
2014	2.9 USD	-0.16 USD	-0.12 USD
2015	2.52 USD	-0.37 USD	-0.25 USD
2016	1.68 USD	-0.71 USD	-1.26 USD
2017	1.95 USD	-0.52 USD	-0.52 USD
2018	2.4 USD	-0.53 USD	-0.55 USD
2019	2.03 USD	-0.74 USD	-0.81 USD
2020	1.7 USD	-1.15 USD	-1.34 USD
2021	1.97 USD	-0.99 USD	-1.4 USD
2022	1.53 USD	-0.63 USD	-0.72 USD
2023e	1.06 USD	0 USD	-1.3 USD
2024e	1.01 USD	0 USD	-1.1 USD
2025e	0.97 USD	0 USD	-0.95 USD

Segmente	2022	2021	2020	2019	2018
Net Product Revenue	-	34.74 백만 U001	24.77 백만 U001	-	-
Net Product Sales	47.09 백만 U001	-	-	-	-
Government Grant Income	1.18 백만 U001	10.89 백만 U001	2.02 백만 U001	-	-
Revenue earned during the period from research and development milestones when those milestones are reached and non-milestone contracts and grants when earned	-	-	-	4.68 백만 U001	5.72 백만 U001
Revenue earned during the period from research and development	112,986 U001	1.16 백만 U001	4.85 백만 U001	-	-
License and Royalty Revenue	1.14 백만 U001	1.03 백만 U001	832,562 U001	-	-

	Net Product Revenue	Net Product Sales	Government Grant Income	Revenue earned during the period from research and development milestones when those milestones are reached and non-milestone contracts and grants when earned	Revenue earned during the period from research and development	License and Royalty Revenue
2018	0 USD	0 USD	0 USD	5.72 백만 USD	0 USD	0 USD
2019	0 USD	0 USD	0 USD	4.68 백만 USD	0 USD	0 USD
2020	24.77 백만 USD	0 USD	2.02 백만 USD	0 USD	4.85 백만 USD	832,562 USD
2021	34.74 백만 USD	0 USD	10.89 백만 USD	0 USD	1.16 백만 USD	1.03 백만 USD
2022	0 USD	47.09 백만 USD	1.18 백만 USD	0 USD	112,986 USD	1.14 백만 USD

Segmente	2022	2021	2020	2019	2018
Net Product Sales	-	-	-	4.8 백만 U001	8.61 백만 U001
Revenue earned during the period from research and development and grants when earned	-	-	-	4.68 백만 U001	5.72 백만 U001
License and Royalty Revenue	-	-	-	938,753 U001	948,773 U001

	Net Product Sales	Revenue earned during the period from research and development and grants when earned	License and Royalty Revenue
2018	8.61 백만 USD	5.72 백만 USD	948,773 USD
2019	4.8 백만 USD	4.68 백만 USD	938,753 USD
2020	0 USD	0 USD	0 USD
2021	0 USD	0 USD	0 USD
2022	0 USD	0 USD	0 USD

날짜	Africa	Asia	Continent of Europe and Region of Middle East	Latin America	United States
2022	7 백만 U001	665,159 U001	4.52 백만 U001	19.27 백만 U001	18.07 백만 U001
2021	5.56 백만 U001	664,579 U001	5.18 백만 U001	18.42 백만 U001	17.99 백만 U001
2020	4.89 백만 U001	824,488 U001	9.91 백만 U001	9.84 백만 U001	7.01 백만 U001
2019	7.56 백만 U001	888,800 U001	6.5 백만 U001	11.81 백만 U001	7.7 백만 U001
2018	8.61 백만 U001	1.39 백만 U001	2.17 백만 U001	11.72 백만 U001	2.85 백만 U001

	Africa	Asia	Continent of Europe and Region of Middle East	Latin America	United States
2018	8.61 백만 USD	1.39 백만 USD	2.17 백만 USD	11.72 백만 USD	2.85 백만 USD
2019	7.56 백만 USD	888,800 USD	6.5 백만 USD	11.81 백만 USD	7.7 백만 USD
2020	4.89 백만 USD	824,488 USD	9.91 백만 USD	9.84 백만 USD	7.01 백만 USD
2021	5.56 백만 USD	664,579 USD	5.18 백만 USD	18.42 백만 USD	17.99 백만 USD
2022	7 백만 USD	665,159 USD	4.52 백만 USD	19.27 백만 USD	18.07 백만 USD

	주식 수량
2003	2.26 백만 Aktien
2004	750,000 Aktien
2005	960,000 Aktien
2006	1.29 백만 Aktien
2007	1.83 백만 Aktien
2008	7.66 백만 Aktien
2009	9.38 백만 Aktien
2010	8.87 백만 Aktien
2011	8.56 백만 Aktien
2012	8.61 백만 Aktien
2013	9.52 백만 Aktien
2014	9.53 백만 Aktien
2015	9.63 백만 Aktien
2016	10.62 백만 Aktien
2017	12.3 백만 Aktien
2018	14.43 백만 Aktien
2019	16.95 백만 Aktien
2020	19.09 백만 Aktien
2021	24.3 백만 Aktien
2022	32.27 백만 Aktien
2023e	32.27 백만 Aktien
2024e	32.27 백만 Aktien
2025e	32.27 백만 Aktien

EPS-예상치	EPS-실제	보고 분기
-0.21	-0.29 (-35.39 %)	2022 Q1
-0.21	-0.47 (-124.77 %)	2021 Q4
-0.19	-0.24 (-23.84 %)	2021 Q3
-0.37	-0.45 (-20.32 %)	2021 Q2
-0.32	-0.22 (31.89 %)	2021 Q1
-0.28	-0.35 (-24.03 %)	2020 Q4
-0.27	-0.28 (-5.58 %)	2020 Q3
-0.4	-0.4 (0.72 %)	2020 Q2
-0.23	-0.25 (-7.71 %)	2020 Q1
-0.25	-0.24 (3.96 %)	2019 Q4
-0.17	-0.22 (-26.87 %)	2019 Q3
-0.16	-0.19 (-22.11 %)	2019 Q2
-0.16	-0.14 (9.68 %)	2019 Q1
-0.17	-0.21 (-22.88 %)	2018 Q4
-0.06	-0.16 (-161.44 %)	2018 Q3
-0.07	-0.12 (-68.07 %)	2018 Q2
-0.14	-0.05 (64.99 %)	2018 Q1
-0.1	-0.16 (-56.86 %)	2017 Q4
-0.11	-0.05 (55.44 %)	2017 Q3
-0.17	-0.18 (-6.95 %)	2017 Q2
-0.2	-0.13 (34.64 %)	2017 Q1
-0.15	-0.21 (-37.25 %)	2016 Q4
-0.17	-0.19 (-12.89 %)	2016 Q3
-0.16	-0.86 (-443.96 %)	2016 Q2
-0.09	-0.03 (67.32 %)	2016 Q1
-0.09	-0.07 (19.26 %)	2015 Q4
-0.07	-0.05 (29.97 %)	2015 Q3
0	-0.07 (0 %)	2015 Q2
-0.11	-0.07 (37.61 %)	2015 Q1
-0.03	-0.05 (-63.4 %)	2014 Q4
-0.02	-0.03 (-47.06 %)	2014 Q3
-0.02	-0.02 (15.97 %)	2014 Q2
-0.01	-0.02 (-96.08 %)	2014 Q1
0.04	-0.03 (-167.87 %)	2013 Q4
0.08	0.07 (-10.49 %)	2013 Q3
-0.04	-0.03 (19.79 %)	2013 Q2
0.02	0.04 (68.07 %)	2013 Q1
0.05	0.06 (30.72 %)	2012 Q4
0.04	-0.04 (-198.04 %)	2012 Q3
0.03	0.04 (30.72 %)	2012 Q2
0	0.08 (0 %)	2012 Q1
0	0 (0 %)	2011 Q2
0	0 (0 %)	2011 Q1
0	0.24 (0 %)	2010 Q4
0	0 (0 %)	2010 Q3
-0.08	0.08 (198.04 %)	2010 Q2
-0.08	0 (100 %)	2008 Q3
-0.08	-0.08 (1.96 %)	2008 Q2
-0.16	-0.08 (50.98 %)	2008 Q1
-0.82	-2.56 (-213.73 %)	2007 Q4
-0.98	-0.56 (42.81 %)	2007 Q3
-1.06	-0.72 (32.13 %)	2007 Q1
-0.98	-1.84 (-87.91 %)	2006 Q4

%-지분	이름	주식	변경
4.25169 %	The Vanguard Group, Inc.	1,561,470	-544
0.76092 %	Geode Capital Management, L.L.C.	279,456	-656
0.56094 %	BlackRock Institutional Trust Company, N.A.	206,009	-185
0.37140 %	Renaissance Technologies LLC	136,400	22,800
0.33504 %	BNY Mellon Asset Management	123,045	-907
0.30292 %	Esfandiari (Javan)	111,251	12,903
0.28987 %	Davis (Katherine Lyon)	106,457	16,314
0.21952 %	Virtu Americas LLC	80,619	80,619
0.18598 %	Northern Trust Investments, Inc.	68,304	0
0.16337 %	Signaturefd, LLC	60,000	-9,300
0.15485 %	Susquehanna International Group, LLP	56,869	56,869
0.14727 %	Potthoff (John Gary Ph.D.)	54,086	16,314
0.14543 %	State Street Global Advisors (US)	53,409	0
0.13999 %	ValMark Advisers, Inc.	51,413	0
0.13999 %	Eberly (Richard L)	51,413	0
0.12499 %	Goldman (Neil A.)	45,903	0
0.10194 %	Two Sigma Investments, LP	37,438	14,353
0.07982 %	Group One Trading, L.P.	29,315	7,628
0.05905 %	Jane Street Capital, L.L.C.	21,688	21,688
0.05721 %	Hightower Advisors, LLC	21,012	0
0.05689 %	Citadel Advisors LLC	20,895	-75,082
0.05541 %	Newbridge Capital Management	20,350	0
0.04857 %	Simplex Trading, LLC	17,836	9,467
0.03768 %	Northern Trust Global Investments	13,839	0
0.02723 %	Running Point Capital Advisors, LLC	10,000	0
0.02678 %	Tower Research Capital LLC	9,834	-757
0.02677 %	Freedom Wealth Alliance, LLC	9,831	9,831
0.02147 %	Caso (Charles)	7,885	7,885
0.02147 %	Angelico (Paul)	7,885	7,885
0.01561 %	Bespalko (David William)	5,734	5,734
0.01332 %	Acheson (David W. K.)	4,893	4,893
0.00958 %	J.P. Morgan Securities LLC	3,520	126
0.00953 %	Riggs Asset Management Company Inc.	3,500	1,325
0.00861 %	Morgan Stanley & Co. LLC	3,162	1
0.00613 %	Wells Fargo Advisors	2,250	1,000
0.00547 %	Cutler Group, LP	2,010	-152
0.00545 %	Antonetti Capital Management, LLC	2,000	0
0.00415 %	Morgan Stanley Smith Barney LLC	1,525	-1,553
0.00313 %	Advisor Group, Inc	1,150	0
0.00272 %	Cornerstone Planning Group LLC	1,000	1,000
0.00170 %	Whittier Trust Company	625	0
0.00147 %	WWM Financial	540	0
0.00136 %	Kistler-Tiffany Advisors	500	0
0.00102 %	Independent Financial Partners	375	0
0.00077 %	BNP Paribas Securities Corp. North America	284	0
0.00068 %	Harbour Investments, Inc	250	250
0.00064 %	Wells Fargo Bank, N.A.	235	46
0.00064 %	BlackRock Financial Management, Inc.	235	0
0.00023 %	BofA Global Research (US)	86	86
0.00012 %	RBC Capital Partners	44	44
0 %	Susquehanna Fundamental Investments, LLC	0	-29,000
0 %	ExodusPoint Capital Management, LP	0	-10,672
0 %	Ergoteles Capital	0	-89,800
0 %	Union Square Park Capital Management, LLC	0	-75,000
0 %	Squarepoint Capital LLP	0	-38,608
0 %	Wolverine Trading, LLC	0	-13,173
0 %	Schonfeld Strategic Advisors LLC	0	-10,800
0 %	BMO Family Office, LLC	0	-7,610
0 %	Ikarian Capital LLC	0	-219,109
0 %	Boothbay Fund Management, LLC	0	-22,832
0 %	Engineers Gate Manager, L.P.	0	-17,361
0 %	Trexquant Investment LP	0	-12,151
0 %	HRT Financial LP	0	-33,463
0 %	LPL Financial LLC	0	-20,885
0 %	NEXT Financial Group, Inc.	0	-6,000
0 %	Focused Wealth Management, Inc.	0	-375
0 %	PDT Partners, LLC	0	-22,978
0 %	Barclays Bank PLC	0	-2,359
0 %	Tibra Equities Europe, Ltd.	0	-109,000
0 %	Dimensional Fund Advisors, Ltd.	0	-4,701
0 %	Principal Funds, Inc.	0	-3,654
0 %	DWS Investments UK Limited	0	-12,696
0 %	Sigma Planning Corporation	0	-19,300
0 %	Assenagon Asset Management S.A.	0	-439
0 %	ProShare Advisors LLC	0	-5,492
0 %	Relative Value Partners Group, LLC	0	-13,991
0 %	Penbrook Management, LLC	0	-83,450
0 %	Phocas Financial Corporation	0	-10,000
0 %	CAPTRUST Financial Advisors	0	-500
0 %	GSA Capital Partners LLP	0	-30,880
0 %	Peak 6 Capital Management, LLC	0	-16,083
0 %	Neuberger Berman, LLC	0	-37,500
0 %	Barclays Capital Inc.	0	-2,182
0 %	Morgan Stanley & Co. International Plc	0	-538
0 %	Marshall Wace LLP	0	-10,977
0 %	Millennium Management LLC	0	-191,303
0 %	LMCG Investments, LLC	0	-3,000
0 %	Gagnon Securities LLC	0	-47,793
0 %	ProFund Advisors LLC	0	-429
0 %	Rafferty Asset Management LLC	0	-22,745
0 %	Rhumbline Advisers Ltd. Partnership	0	-17,866
0 %	Segall Bryant & Hamill, LLC	0	-350,659
0 %	BMO Harris Bank N.A.	0	-2,360
0 %	Perritt Capital Management, Inc.	0	-30,651
0 %	Federated Hermes MDTA LLC	0	-1,106
0 %	Charles Schwab Investment Management, Inc.	0	-41,983
0 %	Legal & General Investment Management Ltd.	0	-2,180
0 %	Vaughan Nelson Investment Management, L.P.	0	-689
0 %	Principal Global Investors (Equity)	0	-3,654
0 %	DWS Investment Management Americas, Inc.	0	-34,000

이름	관계	이주간 상관관계	원월 상관관계	삼개월 상관계수	여섯달 상관관계	일년간 상관관계	이년 상관관계
Bio-Rad Laboratories A	공급업체고객	0,60	0,75	0,88	0,92	0,72	-0,29

What values and corporate philosophy does Chembio Diagnostics represent?

Chembio Diagnostics Inc represents values such as innovation, quality, and commitment in the field of diagnostic testing. The company focuses on developing and commercializing rapid point-of-care diagnostic tests for infectious diseases, including HIV, Zika, and Ebola. With a strong corporate philosophy centered around improving patient outcomes and global health, Chembio Diagnostics Inc strives to provide accurate and reliable diagnostic solutions. Their advanced technologies and extensive expertise empower healthcare professionals to make informed decisions for early detection and efficient management of various medical conditions. Through continuous research and development, Chembio Diagnostics Inc remains dedicated to delivering efficient and effective diagnostic solutions to healthcare systems worldwide.

In which countries and regions is Chembio Diagnostics primarily present?

Chembio Diagnostics Inc is primarily present in the United States of America.

What significant milestones has the company Chembio Diagnostics achieved?

Chembio Diagnostics Inc has achieved several significant milestones. The company secured FDA approval for its rapid HIV diagnostic tests, which provided accurate and timely results. Chembio also received Emergency Use Authorization (EUA) for its COVID-19 antibody test, allowing for rapid and reliable detection of antibodies in individuals. Additionally, the company expanded its global reach by partnering with various organizations and securing distribution agreements worldwide. Chembio Diagnostics Inc has consistently demonstrated innovation and commitment to delivering high-quality diagnostic solutions, making it a prominent player in the healthcare industry.

What is the history and background of the company Chembio Diagnostics?

Chembio Diagnostics Inc. is a leading company in the field of point-of-care diagnostic tests. Established in 1985, Chembio has been dedicated to developing innovative, rapid, and reliable testing solutions for infectious diseases. With a strong commitment to global health, the company focuses on creating advanced diagnostic assays that provide accurate results within minutes, enabling better patient care and disease management. Chembio has built a diverse portfolio of products, including rapid tests for HIV, malaria, Zika virus, and syphilis, among others. Over the years, Chembio Diagnostics Inc. has become renowned for its expertise, quality products, and contributions to global healthcare.

Who are the main competitors of Chembio Diagnostics in the market?

Chembio Diagnostics Inc faces competition from various companies in the market. Some of its main competitors include companies like Abbott Laboratories, Bio-Rad Laboratories, and Quidel Corporation. These companies also operate in the diagnostics industry and offer a range of testing solutions and products, often catering to similar customer needs. Chembio Diagnostics Inc strives to differentiate itself through its innovative technology, product quality, and customer service in order to stay competitive in the market.

In which industries is Chembio Diagnostics primarily active?

Chembio Diagnostics Inc is primarily active in the healthcare industry.

What is the business model of Chembio Diagnostics?

Chembio Diagnostics Inc, a leading biotechnology company, operates with a unique business model focusing on the development, manufacturing, and commercialization of diagnostic solutions. The company specializes in point-of-care testing, providing rapid diagnostic tests for infectious diseases, including HIV, Syphilis, and Zika. Chembio's business strategy revolves around developing proprietary technologies and collaborations for market expansion. By leveraging their expertise in immunoassays, microfluidics, and lateral flow technologies, Chembio aims to improve global healthcare outcomes through accurate and affordable diagnostic solutions. With an emphasis on innovation and strategic partnerships, Chembio Diagnostics Inc continues to make significant contributions to the diagnostics industry.

Chembio Diagnostics 2024의 P/E 비율은 얼마입니까?

Chembio Diagnostics의 P/E 비율은 -0.36입니다.

Chembio Diagnostics 2024의 KUV는 얼마입니까?

Chembio Diagnostics의 P/S 비율은 0.4입니다.

Chembio Diagnostics의 AlleAktien 품질 점수는 얼마인가요?

Chembio Diagnostics에 대한 AlleAktien 품질 점수는 4/10입니다.

Chembio Diagnostics 2024의 매출은 얼마인가요?

예상되는 Chembio Diagnostics 매출은 36.92 백만 USD입니다.

Chembio Diagnostics 2024의 이익은 얼마인가요?

예상되는 Chembio Diagnostics 이익은 -40.29 백만 USD입니다.

Chembio Diagnostics은 무엇을 하나요?

Chembio Diagnostics Inc. is a company specialized in the development and marketing of rapid tests for infectious diseases. The company is headquartered in Hauppauge, New York, and also operates a production facility in Germany. Chembio Diagnostics' business model is based on offering fast, reliable, and cost-effective diagnostic tests that help doctors and medical professionals detect and treat infectious diseases. The company offers test products for various infections such as HIV, hepatitis C, syphilis, malaria, and dengue fever. Chembio Diagnostics has three main business areas: development, production, and distribution of diagnostic tests. In the development area, the company works intensively on developing new and innovative tests for infectious diseases. The company has its own research and development department that collaborates closely with scientists and industry experts to develop new technologies and products. In the production area, Chembio Diagnostics operates a production facility in Germany where diagnostic tests are manufactured. The company has state-of-the-art technologies and facilities to ensure high quality and production efficiency. The marketing of diagnostic tests is the third business area of Chembio Diagnostics. The company works closely with distributors in different countries to sell its products worldwide. Additionally, the company has distribution agreements with major pharmaceutical companies and medical institutions to promote the spread of its tests. Chembio Diagnostics' products are intended for both medical professionals and patients. The tests are frequently used in medical practices, clinics, and hospitals to diagnose and monitor infections. Additionally, the company also offers rapid tests for field use that can be used by emergency services and doctors in remote areas. Chembio Diagnostics positions itself as a leading provider of rapid tests for infectious diseases and is committed to improving the health of people worldwide. The company continues to invest in research and development to develop innovative products that meet the needs of doctors and patients. Overall, Chembio Diagnostics has built a successful business model based on providing high-quality diagnostic tests for infectious diseases. The company has increased its revenue and global presence and continues its success story.

Chembio Diagnostics 배당금은 얼마입니까?

Chembio Diagnostics은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Chembio Diagnostics이 얼마나 자주 배당을 지급하나요?

Chembio Diagnostics의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Chembio Diagnostics ISIN이 무엇입니까?

Chembio Diagnostics의 ISIN은 US1635722093입니다.

Chembio Diagnostics WKN은 무엇인가요?

Chembio Diagnostics의 WKN은 A1JY4D입니다.

Chembio Diagnostics 티커는 무엇인가요?

Chembio Diagnostics의 티커는 CEMI입니다.

Chembio Diagnostics이 얼마만큼의 배당금을 지급합니까?

지난 12개월 동안 Chembio Diagnostics은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Chembio Diagnostics은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Chembio Diagnostics의 배당 수익률은 얼마입니까?

Chembio Diagnostics의 현재 배당 수익률은 입니다.

Chembio Diagnostics의 배당금은 언제 지급되나요?

Chembio Diagnostics은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Chembio Diagnostics의 배당금은 얼마나 안전한가요?

Chembio Diagnostics은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

Chembio Diagnostics의 배당금은 얼마입니까?

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Chembio Diagnostics이(가) 속해 있는 섹터는 어디인가요?

Chembio Diagnostics은 '건강' 섹터에 속합니다.

Wann musste ich die Aktien von Chembio Diagnostics kaufen, um die vorherige Dividende zu erhalten?

Chembio Diagnostics의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

Chembio Diagnostics의 마지막 배당금 지급일은 언제였습니까?

마지막 배당금 지급일은 입니다.

Chembio Diagnostics의 2023년도 배당금은 얼마였습니까?

2023년에 Chembio Diagnostics는 0 USD를 배당금으로 지급했습니다.

Chembio Diagnostics는 어떤 화폐로 배당금을 지급하나요?

Chembio Diagnostics의 배당금은 USD에 지급됩니다.

Chembio Diagnostics 티커	Chembio Diagnostics FIGI
CEMIUSD:XB	BBG00K03RKX8
CEMIUSD:XS	BBG00K03RLC9

2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023e	2024e	2025e
0	3	3	6	9	11	13	16	19	25	29	27	24	17	24	34	34	32	47	49	38	36	35
-	-	-	100.00	50.00	22.22	18.18	23.08	18.75	31.58	16.00	-6.90	-11.11	-29.17	41.18	41.67	-	-5.88	46.88	4.26	-22.45	-5.26	-2.78
-	333.33	33.33	16.67	22.22	27.27	38.46	50.00	47.37	40.00	41.38	37.04	41.67	47.06	45.83	32.35	35.29	25.00	27.66	20.41	26.32	27.78	28.57
0	0	1	1	2	3	5	8	9	10	12	10	10	8	11	11	12	8	13	10	0	0	0
0	-5	-6	-8	-8	-1	0	2	6	0	0	-1	-2	-13	-6	-7	-13	-25	-33	-23	-47	-40	-34
-	-	20.00	33.33	-	-87.50	-	-	200.00	-	-	-	100.00	550.00	-53.85	16.67	85.71	92.31	32.00	-30.30	104.35	-14.89	-15.00
2.26	0.75	0.96	1.29	1.83	7.66	9.38	8.87	8.56	8.61	9.52	9.53	9.63	10.62	12.3	14.43	16.95	19.09	24.3	32.27	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

한 눈에 저평가된 주식을 인식하세요

가격

가격

티커CEMI

ISINUS1635722093

WKNA1JY4D

Chembio Diagnostics 주식 가격

가격

개요

인트라데이 기능

총 수익률 및 상대 가격 변동

해석 및 투자

Chembio Diagnostics 주가 이력

Chembio Diagnostics 주식 매출, EBIT, 이익 US1635722093 · A1JY4D

매출, 이익 & EBIT

매출, EBIT, 소득 이해하기

연간 분석 및 비교

투자 기대치 활용

투자 통찰력

Chembio Diagnostics 매출, 이익 및 EBIT 역사

Chembio Diagnostics 주식 지표

손익계산서

매출 성장

총 이익률

EBIT와 EBIT 마진

수입과 성장

발행 주식

연간 비교의 해석

기대치와 예측

재무 상태표

재무 상태표 이해

자산

부채

자본

년대비 분석

데이터 해석

Chembio Diagnostics 주식 마진 US1635722093 · A1JY4D

마진

매출 총이익률 이해

EBIT 마진 분석

매출 마진에 대한 인사이트

기대치 해석

비교 분석

Chembio Diagnostics 마진 역사

Chembio Diagnostics 주식 매출, EBIT, 주당 순이익 US1635722093 · A1JY4D

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Chembio Diagnostics 매출, 이익 및 EBIT 주당 역사

Chembio Diagnostics 주식 및 주식 분석

Chembio Diagnostics 매출 세분화 US1635722093 · A1JY4D

세그먼트별 매출

세그먼트별 매출 개요

해석 및 사용

투자 전략

Chembio Diagnostics 매출 세분화

세그먼트별 매출

세그먼트별 매출 개요

해석 및 사용

투자 전략

Chembio Diagnostics 매출 세분화

Chembio Diagnostics 지역별 매출 US1635722093 · A1JY4D

세그먼트별 매출

지역별 매출 개요

해석 및 사용법

투자 전략

Chembio Diagnostics 매출 세분화

한눈에 과소평가된 주식을 인식하세요.

Chembio Diagnostics Fair Value에 따른 평가

Fair Value

Fair Value 이해하기

수익 기반 Fair Value

매출 기반 Fair Value

배당 기반 Fair Value

기대치와 예측

비교 분석

Chembio Diagnostics 역사적인 P/E, EBIT 및 P/S에 따른 평가

한눈에 과소평가된 주식을 인식하세요.

티커
CEMI

ISIN
US1635722093

WKN
A1JY4D